Loading…
← CockpitCompetitor Analysis › 301363.SZ Mehow Innovative Ltd. Class AOpen in the cockpit ↗

Mehow Innovative Ltd. Class A301363.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Contract manufacturer designing and producing precision components for medical devices like ventilators and auto-injectors.

≈ A Chinese medical-device CDMO, like a smaller Flex Health SolutionsMomentum neutral 42
Mkt cap
$1.72B
US dollars, full cap
Free float
42%
of shares outstanding
$/day
$46.7M
20-day average traded
Fwd P/E
34.2×
forward earnings
ROIC−WACC
+6.4 pp
WACC 8.9%
Hurdle
+4 pp
Req g minus delivered
Next earnings
155 days
22 Apr 2027
Close · CNYCN¥14.75
1D-4.4%
1W-14.8%
1M-6.9%
3M-15.7%
6M-35.8%
YTD-14.1%
1Y-9.8%
ATR %6.1%
52w lowhigh52.3% off high

What Mehow Innovative does

Contract manufacturer designing and producing precision components for medical devices like ventilators and auto-injectors.

Works as an outsourced design-and-manufacturing partner for device makers, paid per unit shipped once a customer has approved the part. Revenue depends on a limited number of large customers' programmes, and moulding and assembly skill is what it sells.

In one line: A Chinese medical-device CDMO, like a smaller Flex Health Solutions.

Products and services

  • Home ventilator components
  • Auto-injector/drug-delivery devices
  • Precision molds & automation
  • Surgical instruments

Customers

  • Global medical device OEMs

Where it sits in the supply chain

  • Health Care
  • Medical device manufacturing
  • Precision medical-device component CDMO

What could go right

  • Outsourced medical-device manufacturing growth

What could go wrong

  • Customer program concentration
  • OEM insourcing risk

Moat: narrow (process know-how, customer qualification). Design-to-manufacturing qualification with device OEMs is costly to switch mid-program.

Headquarters: Shenzhen, China · Founded: 2010 · Employees: 3,101

Named competitors

Mehow Innovative at a glance

Size Mehow Innovative (301363.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.72B, the 1338th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.75 on 18 Nov 2026.

Performance Over six months the shares fell 35.8%, against +3.5% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue grew 9.9% over the last twelve months (peer median +10.6%); the operating margin is 20.7% (peer median 12.7%).

Valuation It trades at 34.2× forward earnings against a peer median of 25.1× (8th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 6.4 points above its cost of capital (8.9% WACC).

Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 102301363.SZ 69
Six months, rebased to 100: Mehow Innovative against the median of its 20 peers (local-currency closes).

Mehow Innovative financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.79BCN¥1.61BCN¥1.58BCN¥1.33BCN¥1.41B
Revenue growth—+2%+19%-5%—
Gross profitCN¥797MCN¥606MCN¥631MCN¥518MCN¥580M
EBITDAn/aCN¥397MCN¥441MCN¥361MCN¥469M
Net incomeCN¥309MCN¥283MCN¥364MCN¥313MCN¥402M
Free cash flowCN¥169M-CN¥103MCN¥95.2MCN¥107MCN¥180M
Capital expenditureCN¥234MCN¥462MCN¥363MCN¥259MCN¥201M
Total debtCN¥118MCN¥111MCN¥19.0MCN¥45.2MCN¥32.1M

Quarterly statements and history in the cockpit →

Mehow Innovative competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%+20%EMBLALMATXRAYKMTSINSP8086CHEMM7716POLYMEDBFLY66996960268A301087SKANMED688531VITR301363.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Mehow Innovative is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×60×EMBLALMATXRAYINSP8086CHEMM7716POLYMED66991066301087SKANMED688531VITR301363.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mehow Innovative is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%EMBLALMATXRAYINSPCHEMM7716669910666960268A301087SKANVITR301363.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Mehow Innovative is the large dot.

Mehow Innovative competitors and peer comparison

Head to head with its named competitors (301363.SZ vs FLEX vs JBL)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Mehow Innovative 301363.SZ$1.72B-36%+10%21%34.2×16.4%
Flex FLEX$27.7B-43%+18%6%11.7×17.6%
Jabil JBL$25.5B-28%+21%5%14.0×9.2%

How Mehow Innovative compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mehow Innovative against its 20 peers (data as of 18 Nov 2026)
Measure301363.SZPeer medianRank in peer set
1-month return-6.9%-4.4%7th lowest of 21
6-month return-35.8%+3.5%3rd lowest of 20
Distance from 52-week high-52.3%-23.2%4th lowest of 21
Revenue growth (TTM)+9.9%+10.6%11th highest of 21
Operating margin20.7%12.7%4th highest of 21
Forward P/E34.2×25.1×8th most expensive of 18
Growth the price implies (Req g, 7 yrs)16.4%11.2%6th most demanding of 14
Growth delivered (Del g)+12.9%+12.7%7th highest of 14
Hurdle (Req g minus delivered)+3.5 pp-0.6 pp5th most demanding of 14
ROIC minus cost of capital+6.4 pp-0.6 pp6th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%
Nakanishi 7716.TJapan$1.78B+7%+17%21%19.0×4.8%+19.7%
Poly Medicure POLYMED.NSIndia$1.79B+14%+25%16%39.9×n/an/a
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Shandong Weigao Group Medical Polymer 1066.HKHong Kong$1.82B-8%+7%14%8.2×-12.6%+2.1%
Fukuda Denshi 6960.TJapan$1.84B+4%0%19%15.4×-1.6%-1.0%
Rigaku 268A.TJapan$1.85B-54%+9%16%23.1×18.3%+14.5%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%

Questions

Who are Mehow Innovative's main competitors?
Named competitors: Flex (Flex Health Solutions) (FLEX), Jabil Healthcare (JBL). The cockpit's measured peer set (industry) also includes Embla Medical hf (EMBLA.CO), LeMaitre Vascular (LMAT), DENTSPLY SIRONA (XRAY), Kestra Medical Technologies (KMTS), Inspire Medical Systems (INSP), NIPRO (8086.T).
Is Mehow Innovative expensive compared with its peers?
On forward p/e it trades at 34.2× against a peer median of 25.1×, 8th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Mehow Innovative stock performed?
Over six months to 18 Nov 2026 the shares returned -35.8% against +3.5% for the median peer; over one year -9.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.